Martín‐Moro F, Marquet J, Piris M, et al. Survival study of hospitalised patients with concurrent COVID‐19 and haematological malignancies. Br J Haematol. 2020;190:e16-e20.
Scarfò L, Chatzikonstantinou T, Rigolin GM, et al. COVID-19 severity and mortality in patients with chronic lymphocytic leukemia: a joint study by ERIC, the European Research Initiative on CLL, and CLL Campus. Leukemia. 2020;34:2354-2363.
Mato AR, Roeker LE, Lamanna N, et al. Outcomes of COVID-19 in patients with CLL: a multicenter international experience. Blood. 2020;136:1134-1143.
de Simone G, Mancusi C. COVID-19: timing is important. Eur J Intern Med. 2020;77:134-135.
Roeker LE, Knorr DA, Pessin MS, et al. Anti-SARS-CoV-2 antibody response in patients with chronic lymphocytic leukemia. Leukemia. 2020;34:3047-3049.
van der Velden AMT, Mulder AHL, Hartkamp A, et al. Influenza virus vaccination and booster in B-cell chronic lymphocytic leukaemia patients. Eur J Intern Med. 2001;12:420-424.
Sun C, Gao J, Couzens L, et al. Seasonal influenza vaccination in patients with chronic lymphocytic leukemia treated with ibrutinib. JAMA Oncol. 2016;2:1656-1657.
Svensson T, Kättström M, Hammarlund Y, et al. Pneumococcal conjugate vaccine triggers a better immune response than pneumococcal polysaccharide vaccine in patients with chronic lymphocytic leukemia: a randomized study by the Swedish CLL group. Vaccine. 2018;36:3701-3707.
Ma S, Platanias LC. Can early intervention with pharmacotherapy reduce the morbidity and mortality of chronic lymphocytic leukemia? Expert Opin Pharmacother. 2018;19:1171-1175.
ClinicalTrials.gov. Testing the effects of early treatment with venetoclax and obinutuzumab versus delayed treatment with venetoclax and obinutuzumab for newly diagnosed patients with high-risk chronic lymphocytic leukemia or small lymphocytic lymphoma who do not have symptoms, the EVOLVE CLL/SLL Study. Available at: https://clinicaltrials.gov/ct2/show/NCT04269902. Accessed November 17, 2020.
Roschewski M, Lionakis MS, Sharman JP, et al. Inhibition of Bruton tyrosine kinase in patients with severe COVID-19. Sci Immunol. 2020;5:eabd0110.
Alsuliman T, Belghoul M, Choufi B. Ibrutinib treatment through nasogastric tube in a comatose patient with central nervous system localization of mantle cell lymphoma. Case Rep Hematol. 2018;2018:5761627.
Maddox JM, Majid M. Use of ibrutinib via nasogastric (NG) tube & percutaneous endoscopic gastrostomy (PEG) tube. Program and abstracts of the 2016 American Society of Hematology Annual Meeting; December 3-6, 2016; San Diego, California. Abstract 5371.
Rattanawong P, Shen W, Hicham El Masry H, et al. Guidance on short-term management of atrial fibrillation in coronavirus disease 2019. J Am Heart Assoc. 2020;9:e017529.
Treon SP, Castillo JJ, Skarbnik AP, et al. The BTK inhibitor ibrutinib may protect against pulmonary injury in COVID-19–infected patients. Blood. 2020;135:1912-1915.
Nunnery SE, Mayer IA. Management of toxicity to isoform α-specific PI3K inhibitors. Ann Oncol. 2019;30 Suppl 10:x21-x26.